Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

COVID-19 Updates: COVID-19 Resources » Vaccine Update » Updated Visitor Policy » What We're Doing to Keep You Safe »

View All Information for Patients & Visitors »

View the changes to our visitor policy »

View information for Guest Services »

New to MyHealth?

Manage Your Care From Anywhere.

Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.

CLINICAL TRIALS

About Clinical Trials Find a Clinical Trial

CLINICAL TRIALS

About Clinical Trials Find a Clinical Trial

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

Trial ID or NCT#

NCT01146054

Status

NOT RECRUITING

Purpose

This multi-institutional trial aims to evaluate the potential benefit and side effects of adding fractionated stereotactic body radiotherapy/surgery (SBRT) before and after chemotherapy with gemcitabine for locally advanced pancreatic cancer.

Official Title

Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Inclusion Criteria:

3.1.1 Histologically confirmed adenocarcinoma of the pancreas. 3.1.2 Unresectable disease as determined by a pancreatic cancer surgeon and assessment at a GI oncology tumor board (JHU - Johns Hopkins University, SU - Stanford University, or MSKCC - Memorial Sloan Kettering Cancer Center). 3.1.3 Up to 3 weeks of gemcitabine chemotherapy is allowed prior to SBRT. 3.1.4 Pancreatic tumors must be less than 7.5 cm in greatest axial dimension (or <1000 cc in volume) at the time of treatment planning. 3.1.5 No prior upper abdominal or liver radiation therapy. 3.1.6 No chemotherapy within 2 weeks of radiotherapy, or chemotherapy within parameters set by Investigator for each institution. 3.1.7 Age >=18 years. 3.1.8 No infections requiring systemic antibiotic treatment. 3.1.9 Karnofsky >= 70% (see Appendix III). 3.1.10 Patients must have acceptable organ and marrow function as defined below (within 1 month prior to radiotherapy): - leukocytes: >=3,000/microliter (uL) - absolute neutrophil count: >=1,500uL - platelets: >=100,000/uL - total bilirubin: within 1.5 times (1.5X) normal institutional limits - AST (aspartate aminotransferase)(SGOT -Serum glutamic oxaloacetic transaminase)/ALT(alanine aminotransferase)(SGPT-serum glutamic-pyruvic transaminase): <=2.5 X institutional upper limit of normal - creatinine: within normal institutional limits OR - creatinine clearance: >=60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal 3.1.11 The effects of radiation on the developing human fetus at recommended therapeutic doses can result in death of the fetus. If a woman is of child-bearing potential, a negative urine or serum pregnancy test must be demonstrated prior to treatment. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation and for up to 4 weeks following the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 3.1.12 Ability to understand and the willingness to sign a written informed consent document. 3.1.13 Life expectancy > 6 months

Exclusion Criteria:

3.2.1 Patients who have had prior radiotherapy to the upper abdomen. 3.2.2 Patients receiving more than 1 cycle of gemcitabine chemotherapy or other therapy prior to SBRT. 3.2.3 Children are excluded because pancreatic tumors rarely occur in this age group. Furthermore, treatment requires a great deal of patient cooperation including the ability to lie still for several hours in an isolated room. 3.2.4 No laboratory personnel will be included. 3.2.5 Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 3.2.6 Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder cancer, or carcinoma in situ of the cervix. Patients with a previous malignancy without evidence of disease for > 5 years will be allowed to enter the trial. 3.2.7 Pregnant and breastfeeding women are excluded. Women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to 4 weeks after the study are excluded. This applies to any woman who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months, or women on hormone replacement therapy with serum FSH (follicle stimulating hormone) levels greater than 35 IU/mL (international units/milliliter). A negative urine or serum pregnancy test must be obtained within 72 hours prior to the start of study medication in all women of childbearing potential. Male subjects must also agree to use effective contraception for the same period as above.

View All Criteria

Investigator(s)

Jeffrey Norton, MD

Surgical oncologist

Robert L. and Mary Ellenburg Professor of Surgery

Daniel Chang

Radiation oncologist

Sue and Bob McCollum Professor

Brendan C. Visser, MD

Hepatobiliary surgeon, Pancreatic surgeon, Surgical oncologist

Associate Professor of Surgery (General Surgery)

George A. Fisher Jr.

Medical oncologist, Gastrointestinal specialist

Colleen Haas Chair in the School of Medicine

CONTACT

Ccto-office@stanford.edu
(650) 498-7061

SEND MESSAGE

View on ClinicalTrials.gov

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

Trial ID or NCT#

Status

Purpose

Official Title

Eligibility Criteria

Investigator(s)

CONTACT

About this Clinical Trial

Your Message Will Go To

To:

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

Trial ID or NCT#

Status

Purpose

Official Title

Eligibility Criteria

Investigator(s)

CONTACT

About this Clinical Trial

Your Message Will Go To

To: